Low Density Lipoprotein Apheresis

  • Kenjiro Honda
  • Kent Doi


  • Therapeutic plasma exchange volume is usually 3–5 L/session.

  • Removal of positively charged particles as well as low density lipoprotein cholesterol improves focal segmental glomerulosclerosis and peripheral arterial disease.

  • Angiotensin converting enzyme (ACE) inhibitors should be discontinued at least 2–3 days prior to low density lipoprotein (LDL) apheresis.

  • LDL apheresis should be performed with careful attention to its promotion of bleeding tendencies because of the adsorption of endogenous coagulation factors.


Peripheral Arterial Disease Angiotensin Converting Enzyme Inhibitor Familial Hypercholesterolemia Critical Limb Ischemia Familial Hypercholesterolemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Thompson GR, Lowenthal R, Myant NB (1975) Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1:1208–11PubMedCrossRefGoogle Scholar
  2. 2.
    Hobbs HH, Russell DW, Brown MS et al (1990) The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24:133–70PubMedCrossRefGoogle Scholar
  3. 3.
    Ohtake T, Kobayashi S (2009) Masshodoumyakushikkan nitaisuru atarashii chokusetsukanryuu (DHP) chiryo. Jpn J Apher 28:224–9Google Scholar
  4. 4.
    Kobayashi S, Moriya H, Negishi K et al (2003) LDL-apheresis up-regulates VEGF and IGF-I in patients with ischemic limb. J Clin Apher 18:115–9PubMedCrossRefGoogle Scholar
  5. 5.
    Kobayashi S, Moriya H, Maesato K et al (2005) LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J Clin Apher 20:239–43PubMedCrossRefGoogle Scholar
  6. 6.
    Kobayashi S, Oka M, Moriya H et al (2006) LDL-apheresis reduces P-Selectin, CRP and fibrinogen – possible important implications for improving atherosclerosis. Ther Apher Dial 10:219–23PubMedCrossRefGoogle Scholar
  7. 7.
    Kobayashi S (2008) Applications of LDL-apheresis in nephrology. Clin Exp Nephrol 12:9–15PubMedCrossRefGoogle Scholar
  8. 8.
    Mitarai T (2002) Sojoshikyutaikokasho. Sogorinsho 81:547–52Google Scholar
  9. 9.
    Kobayashi S (1998) LDL-Apheresis for diabetic nephropathy: a possible new tool. Nephron 79:505–6PubMedCrossRefGoogle Scholar
  10. 10.
    Aengevaeren WR, Kroon AA, Stalenhoef AF et al (1996) Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 28:1696–704PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.Department of Nephrology and EndocrinologyUniversity Hospital, The University of TokyoTokyoJapan
  2. 2.Department of Emergency and Critical Care MedicineUniversity Hospital, The University of TokyoTokyoJapan

Personalised recommendations